Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 in chronic stable heart failure with reduced or mildly reduced ejection fraction
NL-OMON53896Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing XXB750 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jan 2023; status: active, not recruiting.
02
Drugs
xxb750
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NL-OMON53896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53896.